dopa/baş ağrısı

Bağlantı panoya kaydedilir

Sıralama türünü seçin

Sayfa 1 itibaren 36 Sonuçlar

Albuterol improves response to levodopa and increases skeletal muscle mass in patients with fluctuating Parkinson disease.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

Animal studies indicate that beta(2)-adrenergic receptor agonists enhance transport of levodopa across the blood-brain barrier. Preliminary studies showed improved response to levodopa in patients with Parkinson disease (PD) who were given albuterol as adjunctive therapy. Beta(2)-adrenergic agonists

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

BACKGROUND Motor response fluctuations and dyskinesias compromise long-term levodopa therapy in Parkinson's disease. Variations in plasma levodopa levels contribute to adverse reactions associated with chronic therapy. Therefore, sustained-release levodopa preparations may be associated with less

Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

This open-label phase I trial assessed potential pharmacokinetic interactions between oral levodopa/carbidopa and transdermal rotigotine treatment at steady state. Twenty-four participants with idiopathic restless legs syndrome (12 per group) received levodopa/carbidopa (100 mg/25 mg bid) and

Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

OBJECTIVE To investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic properties of the dopamine transporter antagonist brasofensine (BMS-204756) in patients with Parkinson's disease receiving levodopa/carbidopa treatment. METHODS A 4-period crossover study was performed in 8 men

Investigation of the impact of sarizotan on the pharmacokinetics of levodopa.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

OBJECTIVE To investigate the effect of sarizotan on the pharmacokinetics of levodopa in fixed combination with carbidopa or benserazide. METHODS In this open-label, randomized, crossover study, healthy male subjects (n=16) received levodopa 100 mg t.i.d. over two 5-day periods, alone or in

Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

OBJECTIVE IPX066 is an extended release carbidopa/levodopa formulation designed to rapidly attain and maintain therapeutic plasma concentrations for a prolonged duration, allowing dosing intervals of approximately 6 h. The objective was to assess the efficacy, safety, and impact on quality of life

Levodopa and the progression of Parkinson's disease.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

BACKGROUND Despite the known benefit of levodopa in reducing the symptoms of Parkinson's disease, concern has been expressed that its use might hasten neurodegeneration. This study assessed the effect of levodopa on the rate of progression of Parkinson's disease. METHODS In this randomized,

Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

During a long-term double-blind study, which began February 1985, we have treated 16 patients with Morbus Parkinson or Parkinson's syndrome with deprenyl or identically appearing placebo tablets. The aim of the study is to ascertain whether a reduction of other antiparkinsonian medication,

Effect of levodopa treatment for parkinsonism in welders: A double-blind study.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

BACKGROUND Manganese is known to cause a parkinsonian syndrome similar clinically to Parkinson disease (PD). L-Dopa responsiveness is a hallmark of PD; however, L-dopa's effect on manganese-induced parkinsonism is not well defined. OBJECTIVE To access the efficacy and safety of L-dopa therapy in a

A randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

The objective of this study was to establish the maximum tolerated dose of the low affinity non-competitive N-methyl-D-aspartate receptor antagonist remacemide in patients who have Parkinson's disease with response fluctuations or dyskinesias, or both. A total of 33 patients were randomly assigned

[A report from neurological practice].

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

It was one of the great pleasures to have fulfilled my long-held dream in 1986, newly opened the Kitasato University East Hospital (KUEH). In 1965, I served at chronic ward of Baltimore City Hospitals as a resident of neurology, where most of the patients were relaxed and enjoyed their hospital

Paediatric neurological melioidosis: a rehabilitation case report.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

BACKGROUND Melioidosis is a rare condition, endemic to northern Australia and south-east Asia, caused by an infection from the bacteria Burkholderia pseudomallei. The largest epidemiological review to date describes 540 cases of melioidosis seen at Darwin Hospital, in northern Australia, over

Spotlight on rotigotine transdermal patch in Parkinson's disease.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

Rotigotine transdermal patch (Neupro(®)) [referred to here as rotigotine] is a non-ergolinic dopamine agonist that is available in the EU as monotherapy for the treatment of early Parkinson's disease and as combination therapy with levodopa throughout the course of the disease. Daily application of

[Choosing a dopamine agonist in Parkinson's disease].

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

The number of dopamine agonists (DA) used in Parkinson's disease (PD) is gradually increasing. They have different affinity to the dopamine receptor subtypes. When choosing one of these drugs one should consider its efficacy in monotherapy in early phase and in combined therapy with levodopa in

Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

Quetiapine is an atypical antipsychotic with clozapine-like pharmacology but without associated agranulocytosis. We report our complete experience with quetiapine for the treatment of drug-induced psychosis (DIP) in Parkinson's disease (PD). Thirty-five patients with PD and DIP aged 75 years (range,

Facebook sayfamıza katılın

Herbal & Natural Medicine

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı

55 dilde çalışır
Bilim destekli bitkisel kürler
Görüntüye göre bitki tanıma
Etkileşimli GPS haritası - bölgedeki bitkileri etiketleyin (yakında)
Aramanızla ilgili bilimsel yayınları okuyun
Şifalı bitkileri etkilerine göre arayın
İlgi alanlarınızı düzenleyin ve haber araştırmaları, klinik denemeler ve patentlerle güncel kalın

Bir belirti veya hastalık yazın ve yardımcı olabilecek bitkiler hakkında bilgi edinin, bir bitki yazın ve karşı kullanıldığı hastalıkları ve semptomları görün.
* Tüm bilgiler yayınlanmış bilimsel araştırmalara dayanmaktadır